Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07467148

Placental Thickness -To-Fetal Weight Ratio as a Predictor of Adverse Pregnancy Outcome

The aim of this study is to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

20 year–45 year

Sex eligibility

Female

Study type

Observational

About this study

The placenta is a vital organ that ensures normal fetal growth and development throughout pregnancy by mediating the exchange of oxygen, nutrients, waste products, and essential hormones between the mother and the fetus (1). Any structural or functional abnormality of the placenta can adversely affect fetal growth and pregnancy outcome, highlighting the importance of placental assessment in antenatal care (2).

Adverse pregnancy outcomes, including intrauterine growth restriction (IUGR), preterm birth, low birth weight, preeclampsia, fetal distress, and perinatal mortality, remain major contributors to maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies allows timely interventions, closer surveillance, and improved perinatal outcomes (3). However, advances in ultrasonography and antenatal care, reliable, non-invasive, and easily measurable predictors of adverse outcomes are still limited (4).

Ultrasonographic evaluation of placental morphology has emerged as a practical, non-invasive, and widely accessible method to assess placental health. Among the various parameters, placental thickness reflects placental growth, maturation, and potentially its functional capacity, correlating with gestational age and fetal weight in normal pregnancies. Abnormal placental thickness either decreased or increased has been associated with maternal and fetal pathological conditions (5).

A thin placenta is frequently linked to preeclampsia, IUGR, and chorioamnionitis, whereas a thick placenta defined as more than 3 cm before 20 weeks of gestation and greater than 5 cm at term is observed in Rh-negative pregnancies, gestational diabetes mellitus, and intrauterine infections, particularly primary maternal cytomegalovirus infection (6). Placentomegaly may also be associated with fetal anemia or hromosomal abnormalities such as triploidy, and may result from inflammation, edema, or compensatory hypertrophy secondary to placental insufficiency (7).

Maternal disorders often affect both the fetus and the placenta, making abnormal placental growth a potential marker for impaired fetal growth and adverse neonatal outcomes. Nevertheless, the predictive value of placental thickness alone remains uncertain (8).

Given its simplicity, reproducibility, and cost-effectiveness, ultrasonographic measurement of placental thickness and particularly the placental thickness-to-fetal weight ratio may provide a valuable tool for early detection of high-risk pregnancies. This could allow obstetricians to implement timely interventions, optimize delivery planning, and improve maternal and neonatal outcomes (9). Therefore, this study aims to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • a. Inclusion criteria: Singleton pregnancy. Gestational age between 28-38 weeks. Mothers willing to participate and provide informed consent.

Exclusion criteria

  • Multiple pregnancies (twins, triplets,etc.) Known congenital fetal anomalies Maternal chronic medical conditions affecting fetal growth (e.g pre-existing diabetes, hypertension, renal disease) Intrauterine fetal demise Inability or refusal to provide informed consent

Treatment and study plan

Primary outcomes

  1. The rate of occurrence of adverse pregnancy outcomes, including IUGR, preterm birth, low birth weight, fetal distress, NICU admission, or perinatal mortality

    Time frame: From aug 2026 to aug 2029

    Correlation of placental thickness-to-fetal weight ratio with individual adverse pregnancy outcomes

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Mohamed Abbas, Professor

CONTACT

[email protected]

01003385183

Radia Atef Elzokm, Resident doctor

CONTACT

[email protected]

01202170497

Sponsors and collaborators

Lead sponsor

Radia Atef Elzokm

Other

Registry information

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Mar 12, 2026
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.